Skip to main content

Market Overview

European Officials Seek To Garner Support For AstraZeneca COVID-19 Shot: CNBC

European Officials Seek To Garner Support For AstraZeneca COVID-19 Shot: CNBC
  • European officials are under pressure to reverse restrictions on who can receive the Oxford-AstraZeneca Plc’s (NYSE: AZN) coronavirus vaccine and attract support for the shot, CNBC reports.
  • Yesterday, France recommended the AstraZeneca shot to anyone under 75 (up from a previous age limit of 65), including those with pre-existing health problems.
  • Speaking to the BBC, Carsten Watzl, head of the German Society for Immunology, urged Chancellor Angela Merkel to take the vaccine live on TV to show it’s safe.
  • The European Medicines Agency approved the AZN-Oxford vaccine in January. Still, France and Germany’s health regulators, among others in Europe, only approved the vaccine for the under-65s, saying there was not enough evidence to prove the vaccine’s effectiveness in the higher age group.
  • South Africa halted the use of AstraZeneca’s vaccine after a small early data suggested that AZN’s jab has limited protection against mild disease caused by the variant.
  • Earlier today, Reuters reported that real-world data involving older age groups have shown that the AstraZeneca-Oxford University vaccine effectively prevents COVID-19 infection, hospitalizations, and deaths.
  • WHO listed two versions AZN-Oxford’s vaccine for emergency use and said the vaccines are safe for those above 18 years old, including those over 65.
  • Price Action: AZN shares are down 0.4% at $47.9 in market trading hours on the last check Tuesday.
  • Image Courtesy: Wikimedia

Related Articles (AZN)

View Comments and Join the Discussion!

Posted-In: CNBC COVID-19 VaccineBiotech News Health Care FDA Global General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at